UnitedHealth Group

Pharmacoepidemiology, Fourth Edition

Volumn , Issue , 2007, Pages 271-280

  Shatin, Deborah ^a   Rawson, Nigel S B ^a,b   Stergachis, Andy ^c  

^a Center for Health Care Policy and Evaluation   (United States)

^b GLAXOSMITHKLINE   (Canada)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adverse event evaluation; Center for Health Care Policy and Evaluation; International Classification of Diseases (ICD 9 CM) and current procedural terminology (CPT 4) codes; Postmarketing surveillance and pharmacoepidemiologic research; Psychotropic drug ambulatory use; Public health research databases; Risk communication effort impact; UnitedHealth Group; UnitedHealth Group affiliated health plans

Indexed keywords

EID: 84889331385     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059876.ch17     Document Type: Chapter

References (29)

1. Shatin D, Drinkard C, Stergachis A. UnitedHealth Group. In: Strom BL, ed., Pharmacoepidemiology, 3rd edn. Chichester: John Wiley & Sons, 2000; pp. 295-305.
2. Enger C, Cali C, Walker AM. Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. Pharmacoepidemiol Drug Saf 2002, 11: 477-86.
3. Cole JA, Loughlin JE, Ajene AN, Rosenberg DM, Cook SE, Walker AM. The effect of zanamivir treatment on influenza complications: a retrospective cohort study. Clin Ther 2002; 24: 1824-39.
4. Tuckson R. Costs of health care administration in the United States and Canada. N Engl J Med 2003; 349: 2462-3.
5. Selby JV. Linking automated databases for research in managed care settings. Ann Intern Med 1997; 127: 719-24.
6. Shatin D. Organizational context and taxonomy of health care databases. Pharmacoepidemiol Drug Saf 2001; 10: 367-71.
7. McCarthy DB, Shatin D, Drinkard CR, Kleinman JH, Gardner JS. Medical records and privacy: empirical effects of legislation. Health Serv Res 1999; 34: 417-25.
8. Kramarz P, France EK, DeStefano F, Black SB, Shinefield H, Ward JI et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J 2001; 20: 410-16.
9. Shatin D, Manda B. Vaccine safety: a case study of the impact of privacy concerns on public health research. Presentation at the Office of Research Integrity Conference, Potomac, MD, November 2002.
10. Brook RH, Lohr KN. Efficacy, effectiveness, variations, and quality: boundary-crossing research. Med Care 1985; 23: 710-22.
11. Iezzoni LI. Assessing quality using administrative data. Ann Intern Med 1997; 127: 666-74.
12. Hui SL. Measuring quality, outcomes, and cost of care using large databases. Ann Intern Med 1997; 127: 665.
13. Rawson NSB, D'Arcy C. "Validity" and reliability: idealism and reality in the use of computerized health care databases for pharmacoepidemiological research. Post Market Surveill 1991; 5: 31-55.
14. Wray NP, Ashton CM, Kuykendall DH, Hollingsworth JC. Using administrative databases to evaluate the quality of medical care: a conceptual framework. Soc Sci Med 1995; 40: 1707-15.
15. Rawson NSB, D'Arcy C. Assessing the validity of diagnostic information in administrative health care utilization data: experience in Saskatchewan. Pharmacoepidemiol Drug Saf 1998; 7: 389-98.
16. Rawson NSB. Health care utilization databases [editorial]. Can J Clin Pharmacol 1998; 5: 203-4.
17. Shatin D, Drinkard CR. Ambulatory use of psychotropics by employer-insured children and adolescents in a national managed care organization. Ambul Pediatr 2002; 2: 111-19.
18. Shatin D, Schech SD, Brinker A. Ambulatory use of ticlopidine and clopidogrel in association with percutaneous coronary revascularization procedures in a national managed care organization. J Interven Cardiol 2002; 15: 181-6.
19. Imura H. A novel antidiabetic drug, troglitazone: reason for hope and concern [editorial]. N Engl J Med 1998; 338: 908-9.
20. Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001; 286: 831-3.
21. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129: 36-8.
22. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ et al. Troglitazone-induced hepatic failure leading to liver transplantation: a case report. Ann Intern Med 1998; 129: 38-41.
23. Shibuya A, Watanabe M, Fujita Y, Saigenji K, Kuwao S, Takahashi H et al. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 1998; 21: 2140-3.
24. Herrine SK, Choudhary C. Severe hepatotoxicity associated with troglitazone [letter]. Ann Intern Med 1999; 130: 163-4.
25. Murphy EJ, Davern TJ, Shakil AO, Shick L, Masharani U, Chow C et al. Troglitazone-induced fulminant hepatic failure. Dig Dis Sci 2000; 45: 549-53.
26. Jagannath S, Rai R. Rapid-onset subfulminant liver failure associated with troglitazone [letter]. Ann Intern Med 2000; 132: 677.
27. Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 2003; 98: 175-9.
28. Shatin D, Rawson NSB, Braun MM, Manda B, Curtis J, Moreland LW et al. Impact of risk communication on tuberculosis testing for infliximab users [abstract]. Pharmacoepidemiol Drug Saf 2003; 12 (suppl 1): S129-30.
29. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098-104.